$590.1 M

CYDY Mkt cap, 27-Mar-2020
Cytodyn Net income (Q2, 2020)-14.9 M
Cytodyn EBIT (Q2, 2020)-12.1 M
Cytodyn Cash, 30-Nov-2019409.5 K
Cytodyn EV589.8 M

Cytodyn Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

R&D expense

530.0k619.8k4.0m15.2m13.7m20.2m38.2m42.5m

General and administrative expense

5.5m6.2m3.1m3.3m5.8m6.8m7.3m12.1m

Operating expense total

6.0m6.8m7.1m18.4m19.5m27.0m45.6m54.6m

Depreciation and amortization

352.4k360.6k361.6k366.4k356.1k1.2m

EBIT

(7.5m)(8.0m)(8.1m)(19.6m)(21.2m)(27.3m)(45.9m)(55.9m)

Interest expense

2.6k224.7k

Interest income

1.2k7.8k2.2k7.9k15.2k3.6k4.3k

Pre tax profit

(7.5m)(9.6m)(12.4m)(25.1m)(25.7m)(25.8m)(50.1m)(59.0m)

Income tax expense

(2.8m)

Net Income

(7.5m)(9.6m)(12.4m)(25.1m)(25.7m)(25.8m)(50.1m)(56.2m)

Cytodyn Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

285.0k603.7k4.9m1.1m9.6m1.8m1.2m2.6m

Accounts Receivable

Prepaid Expenses

66.0k139.8k488.8k253.8k207.3k227.2k107.2k

Inventories

Current Assets

1.0m840.5k5.4m2.0m11.5m6.1m3.3m5.4m

PP&E

800.016.8k24.2k17.3k11.2k29.3k

Total Assets

1.1m4.2m8.4m4.7m13.8m8.1m4.9m20.9m

Accounts Payable

831.3k1.1m1.3m5.0m2.5m4.3m15.8m16.2m

Short-term debt

328.3k1.6m

Current Liabilities

5.0m3.2m2.2m10.7m3.6m6.1m16.7m26.9m

Long-term debt

1.2m2.3m

Non-Current Liabilities

3.0m1.3m2.9m

Total Debt

1.5m1.6m1.6m1.1m

Total Liabilities

5.0m4.4m4.5m15.4m3.6m9.2m18.1m29.8m

Common Stock

15.2m16.2m30.4m35.8m149.5k216.9k329.6k

Preferred Stock

452.0k274.1k266.3k247.6k92.092.0

Additional Paid-in Capital

8.0m17.5m20.1m24.8m107.3m121.7m159.8m220.1m

Retained Earnings

(46.4m)(71.5m)(123.0m)(173.1m)(229.4m)

Total Equity

(4.0m)(223.9k)3.9m(10.7m)10.2m(1.1m)(13.2m)(8.9m)

Debt to Equity Ratio

-6.6 x-0.2 x0.2 x-1 x

Debt to Assets Ratio

0.4 x0.3 x0.1 x0.1 x

Financial Leverage

-0.3 x-18.6 x2.1 x-0.4 x1.4 x-7.3 x-0.4 x-2.3 x

Quarterly

USDQ2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

129.8k1.8m1.4m412.0k676.5k10.1m7.4m2.3m2.4m1.7m2.8m3.3m10.2m4.4m8.8m7.8m946.2k1.3m4.9m4.7m772.4k1.6m1.8m409.5k

Accounts Receivable

63.6k

Prepaid Expenses

30.7k36.6k34.0k105.3k141.0k257.5k487.8k398.8k231.2k185.5k260.1k223.9k276.5k338.9k221.8k181.0k294.4k265.7k338.4k200.9k232.5k272.6k623.7k

Current Assets

934.0k2.5m2.0m940.8k1.0m10.5m8.0m2.7m2.8m1.9m3.6m4.1m12.2m7.1m13.6m12.7m4.3m4.7m6.6m7.5m3.9m4.5m3.2m3.2m

PP&E

1.0k900.01.1k2.2k10.6k10.0k27.8k25.1k21.5k18.8k16.1k22.9k17.9k18.8k15.7k14.0k12.4k12.0k10.1k8.7k31.3k37.1k

Total Assets

981.1k2.6m5.6m4.5m4.4m13.6m11.0m5.6m5.7m4.7m6.1m6.6m14.6m9.3m15.7m14.8m6.1m6.5m8.3m9.0m20.4m20.4m18.4m17.9m

Accounts Payable

1.5m755.6k1.1m899.9k933.9k814.8k738.1k1.4m1.8m2.2m4.9m4.5m2.4m2.9m5.9m5.2m5.7m9.7m11.7m20.7m18.9m14.9m12.0m18.7m

Short-term debt

5.6m5.9m670.1k294.1k248.4k2.7m

Current Liabilities

6.7m5.0m5.1m3.9m3.5m2.5m2.3m2.2m4.6m6.6m12.9m9.3m3.4m3.0m6.3m5.4m11.1m16.7m12.6m24.1m24.0m22.3m23.1m29.7m

Long-term debt

257.3k9.0k1.3m1.6m2.0m2.5m102.1k79.2k

Non-Current Liabilities

4.0m4.0m3.4m2.5m3.3m4.7m4.5m4.4m2.1m1.8m

Total Debt

5.9m5.9m2.0m294.1k248.4k2.5m3.0m1.6m1.6m102.1k79.2k

Total Liabilities

7.3m5.0m5.3m4.6m4.9m4.2m4.3m7.4m8.4m12.9m9.3m3.4m3.0m10.3m9.3m14.5m19.3m15.9m28.8m28.5m26.7m25.2m31.5m

Common Stock

9.0m14.8m15.9m16.4m17.2m30.3m30.4m32.3m32.6m79.6k91.1k118.4k124.9k138.2k149.5k152.8k165.1k208.9k233.9k290.8k304.7k383.6k399.3k

Preferred Stock

1.6m731.0k405.7k363.5k274.1k274.1k266.3k266.3k259.5k95.095.095.095.095.092.092.092.092.092.092.092.0

Additional Paid-in Capital

6.7m7.0m16.0m16.8m18.9m19.4m19.7m20.2m20.9m21.3m73.6m82.9m101.8m108.7m113.3m121.4m126.1m132.6m155.7m167.5m193.5m207.9m238.5m246.6m

Retained Earnings

(54.8m)(57.5m)(80.4m)(85.7m)(90.7m)(102.6m)(108.0m)(116.2m)(134.6m)(145.6m)(163.5m)(187.6m)(201.9m)(214.4m)(245.6m)(260.6m)

Total Equity

(6.4m)(2.5m)218.4k(127.3k)(420.4k)9.5m6.8m680.2k(1.7m)(3.7m)(6.7m)(2.7m)11.2m6.3m5.4m5.4m(8.4m)(12.8m)(7.6m)(19.8m)(8.1m)(6.2m)(6.8m)(13.6m)

Debt to Equity Ratio

27 x-46.5 x-4.8 x0 x0 x-0.7 x-0.4 x-0.6 x0.1 x0 x

Debt to Assets Ratio

1.1 x1.3 x0.5 x0 x0 x0.5 x0.5 x0.2 x0.1 x0 x

Financial Leverage

-0.2 x-1 x25.5 x-35.2 x-10.6 x1.4 x1.6 x8.2 x-3.4 x-1.3 x-0.9 x-2.4 x1.3 x1.5 x2.9 x2.7 x-0.7 x-0.5 x-1.1 x-0.5 x-2.5 x-3.3 x-2.7 x-1.3 x

Cytodyn Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(7.5m)(9.6m)(12.4m)(25.1m)(25.7m)(25.8m)(50.1m)(56.2m)

Depreciation and Amortization

2.0k222.7k352.4k360.6k361.6k366.4k356.1k1.2m

Accounts Payable

62.1k924.5k176.1k7.4m(5.4m)1.5m12.4m1.7m

Cash From Operating Activities

(4.4m)(3.4m)(7.4m)(12.0m)(24.8m)(26.7m)(29.9m)(50.5m)

Purchases of PP&E

(3.1k)(19.2k)(18.6k)(11.9k)(11.1k)(25.7k)

Cash From Investing Activities

(3.5m)(19.2k)(18.6k)(11.9k)(11.1k)(45.3k)

Short-term Borrowings

(500.0k)(789.1k)(259.2k)

Dividends Paid

(1.5k)

Cash From Financing Activities

3.6m7.2m11.7m8.2m33.4m18.9m29.4m52.7m

Net Change in Cash

(752.8k)318.7k4.3m(3.8m)8.6m(7.9m)(544.1k)2.2m

Interest Paid

2.6k224.7k312.0k203.9k26.9k9.2k

Income Taxes Paid

3.1k

Quarterly

USDQ2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(2.7m)(4.1m)(4.7m)(7.1m)(2.6m)(6.2m)(9.4m)(3.4m)(8.4m)(11.1m)(8.9m)(14.2m)(19.2m)(5.4m)(10.8m)(18.9m)(11.6m)(22.6m)(40.5m)(14.4m)(28.7m)(41.3m)(16.2m)(31.0m)

Depreciation and Amortization

1.2k1.6k825.03.9k87.7k175.6k263.7k89.9k180.0k270.2k90.2k180.4k270.6k92.6k185.1k276.2k89.1k178.3k267.4k89.0k243.8k747.7k531.0k1.0m

Accounts Payable

570.3k(166.5k)772.9k831.5k(7.6k)(625.2k)(552.1k)270.7k738.2k824.9k350.1k(5.5m)(541.2k)2.8m1.8m1.5m6.3m8.0m5.0m3.3m(720.9k)(4.0m)2.7m

Cash From Operating Activities

(1.3m)(2.9m)(1.2m)(2.4m)(804.7k)(2.9m)(5.6m)(2.6m)(5.3m)(7.8m)(5.2m)(8.5m)(19.6m)(6.3m)(10.8m)(19.6m)(7.0m)(12.9m)(22.9m)(9.0m)(26.2m)(41.0m)(15.2m)(22.0m)

Purchases of PP&E

(1.1k)(3.1k)(2.3k)(11.2k)(11.2k)(16.1k)(16.1k)(3.5k)(3.5k)(7.9k)(2.3k)(2.3k)(3.2k)(4.7k)(13.5k)

Cash From Investing Activities

(3.5m)(3.5m)(2.3k)(11.2k)(11.2k)(16.9k)(16.1k)(16.1k)(3.5k)(3.5k)(7.9k)(2.3k)(2.3k)(3.2k)(4.7k)(13.5k)

Short-term Borrowings

(250.0k)(250.0k)(789.1k)(789.1k)(259.2k)(850.0k)

Dividends Paid

(1.5k)

Cash From Financing Activities

390.0k3.6m5.8m6.0m879.9k12.4m12.4m2.8m4.6m7.0m10.7m28.7m1.1m9.9m17.7m6.2m12.4m26.1m12.5m25.7m41.3m13.5m19.7m

Net Change in Cash

(908.0k)742.1k1.1m127.1k72.8k9.5m6.8m(2.5m)(3.2m)1.8m2.2m9.2m(5.2m)(830.5k)(1.8m)(829.3k)(478.7k)3.2m3.5m(459.1k)362.2k(1.7m)(2.3m)

Interest Paid

3.9k4.0k48.7k55.7k26.6k278.5k165.4k3.5k142.9k170.9k26.9k26.9k9.2k9.8k255.5k

Income Taxes Paid

2.2k2.2k2.2k

Cytodyn Ratios

USDY, 2019

EV/EBIT

-48.7 x

EV/CFO

-26.8 x

Financial Leverage

-1.3 x